Basimglurant: Development discontinued

Roche discontinued development of RG7090 to treat Fragile X syndrome after the compound missed the primary and secondary endpoints in the double-blind, placebo-controlled, international Phase II Fragxis trial. Specifically, RG7090 missed the primary endpoint of improving ADAMS total score from baseline to week 12 vs. placebo. RG7090 also missed secondary endpoints of improving ADAMS factor score, ABC total and factor scores, CGI-I, CGI-S, SRS and VAS scores vs. placebo. The trial enrolled 183 adults and adolescents with Fragile X syndrome to receive placebo or once-daily 0.5 or 1.5 mg oral RG7090 for 12 weeks. ...